Keyphrases
Acquired Resistance
11%
Advanced Stage
11%
Anticancer
11%
Apoptosis
11%
Apoptotic Pathway
11%
Bcl-x
22%
Cancer Cell Killing
11%
Cancer Model
11%
Cancer Targeting
11%
Cellular Mechanisms
11%
Chemotherapy Drugs
11%
Co-delivery
11%
Combination Therapy
100%
Cytotoxicity
11%
Drug Resistance
55%
Duration of Action
11%
Endosomal
11%
Endosomal Escape
11%
Endosome
11%
First-line Chemotherapy
11%
Functional Delivery
22%
In Vivo Microenvironment
11%
In(III)
11%
Intracellular Drug Concentration
11%
Intrinsic Resistance
11%
Laser Activation
11%
Leading Causes of Death
11%
Lethal Cancer
11%
Metastasizing
11%
Metastatic Cancer
11%
Micrometastasis
11%
Monotherapy
11%
Multidrug Resistance Protein 1 (MDR1)
22%
Multiple Modes
11%
Nanoparticles
44%
Non-productive
11%
Oligonucleotide Therapeutics
100%
Oligonucleotides
55%
Ovarian Cancer
100%
Ovarian Cancer Cells
33%
Paclitaxel
11%
Photodynamic Therapy
100%
Photodynamic Therapy Agents
11%
Resistance Mechanisms
11%
Site of Action
22%
Small Interfering RNA (siRNA)
22%
Specific Genes
22%
Specific Intent
11%
Splice-switching Oligonucleotides
22%
Sublethal
11%
Survivability
11%
Synergism
22%
Synergistic Action
11%
Targeted Nanoparticles
11%
Therapeutic Action
22%
Therapeutic Oligonucleotides
11%
Treatment Failure
11%
Tumor
11%
Two-level
11%
Ultrasmall
11%
Medicine and Dentistry
Cancer Cell
33%
Cancer Model
8%
Cell Killing
8%
Cellular Mechanism
8%
Combination Therapy
100%
Cytotoxicity
8%
Drug Resistance
41%
Endosome
8%
First-Line Chemotherapy
8%
Malignant Neoplasm
8%
Metastatic Carcinoma
8%
Micrometastasis
8%
Monotherapy
8%
Multidrug Resistance Protein 1
16%
Nanoparticle
41%
Neoplasm
8%
Oligonucleotide
58%
Oligonucleotide Therapy
100%
Ovarian Cancer
100%
Paclitaxel
8%
Pharmacotherapy
8%
Photochemotherapy
100%
Programmed Cell Death
8%
Small Interfering RNA
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cancer Model
8%
Combination Therapy
100%
Cytotoxicity
8%
Drug Concentration
8%
Drug Resistance
41%
First-Line Chemotherapy
8%
Malignant Neoplasm
16%
Metastasis
8%
Micrometastasis
8%
Monotherapy
8%
Multidrug Resistance Protein 1
16%
Nanoparticle
41%
Neoplasm
8%
Oligonucleotide
100%
Ovary Cancer
100%
Paclitaxel
8%
Photodynamic Therapy
100%
Small Interfering RNA
16%
Synergism
16%